WorkspaceResearch
BFBIOPHARMACEUTICALSAlpha Score••Free accountSep-26

BF Biosciences Ltd

Shariah compliant
Last close
Rs138.24
+2.20%
3 monthsAs of 19 Nov
BusinessAverageGrowthGrew 30%+last yearValueCore planHealthStrongDividendNone

A strong balance sheet and the price in an uptrend. Priced above its peers.

Working

  • Debt is 30% of equity in the latest quarter.
  • Revenue up 14% on the same quarter last year.
  • Short-term assets cover short-term bills 1.8 times in the latest quarter.

To watch

  • P/E 18.6 against a sector median of 11.9.
  • Free cash flow negative, Rs 864m out last year, after Rs 655m out the year before.
  • Operating margin 12% over the last twelve months, below its average of 16% over the last 3 years.
Full analysis · free account

Keep reading BFBIO: business, price trend and value

How good the business is, where its support zone sits, what it may be worth, its health, dividends, peers and latest results open with a free account.

Latest results

Quarter: Jul–Sep 2026

In the Jul–Sep 2026 quarter, BFBIO's sales rose 14% to Rs 2.8bn, from Rs 2.4bn, and profit after tax rose 16% to Rs 184.9mn, from Rs 160.0mn (compared with Jul–Sep 2025).

Earnings per share were Rs 2.09, against Rs 1.81 a year earlier.

At Rs 138.24, BFBIO trades at 20.0 times earnings.

P/E ratio
20.0
Dividend yield
0.0%
Dividend payout
0%
of earnings
Return on equity
12%
Net margin
7.0%
last 12 months
Debt to equity
0.30

BFBIO quarterly results

Reported figures
QuarterSalesProfit after taxNet marginEPSDividend / share
Jul–Sep 2026Rs 2.8bnRs 184.9mn6.6%Rs 2.09—
Apr–Jun 2026Rs 2.2bnRs 166.1mn7.5%Rs 1.89—
Jan–Mar 2026Rs 2.1bnRs 118.0mn5.5%Rs 1.33—
Oct–Dec 2025Rs 2.7bnRs 188.0mn7.0%Rs 2.13—
Jul–Sep 2025Rs 2.4bnRs 160.0mn6.6%Rs 1.81—
Apr–Jun 2025Rs 1.6bnRs 129.0mn7.9%Rs 1.45—
Jan–Mar 2025Rs 1.5bnRs 125.0mn8.3%Rs 1.40—
Oct–Dec 2024Rs 1.3bnRs 80.0mn6.0%Rs 0.90—

BFBIO annual results and dividends

Reported figures
YearSalesProfit after taxEPSDividend / share
Year to Jun 2026Rs 9.5bnRs 632.1mnRs 7.16—
Year to Jun 2025Rs 5.8bnRs 447.0mnRs 5.52—
Year to Jun 2024Rs 3.7bnRs 386.0mnRs 6.09—
Year to Jun 2023Rs 1.8bnRs 150.0mnRs 2.35—

Balance sheet and price

Balance sheet as of Sep 2026
Total assets
Rs 9.7bn
Shareholders' equity
Rs 5.5bn
Cash & bank
Rs 178.3mn
Total debt
Rs 1.7bn
Current ratio
1.81
3-month high
Rs 138.24
3-month low
Rs 119.97
1-month change
+10.1%
3-month change
+1.7%

Read more about BFBIO

Other pharmaceuticals companies

BFBIO: common questions

What is BFBIO's share price?

BF Biosciences Ltd (BFBIO) last closed at Rs 138.24 on the Pakistan Stock Exchange.

Does BFBIO pay a dividend?

BF Biosciences Ltd reported no dividend for the year to Jun 2026.

What were BFBIO's latest results?

In the Jul–Sep 2026 quarter, BFBIO's sales rose 14% to Rs 2.8bn, from Rs 2.4bn, and profit after tax rose 16% to Rs 184.9mn, from Rs 160.0mn (compared with Jul–Sep 2025).

What is BFBIO's P/E ratio?

At Rs 138.24, BFBIO trades at 20.0 times its earnings.

Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.